Testing empagliflozin after a stroke with unknown cause
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests if a diabetes drug called empagliflozin can help the heart's left atrium work better in people who have had a stroke with no known cause. You may join if you are getting a heart monitor device implanted to look for hidden irregular heartbeats.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You had an ischemic stroke or transient ischemic attack (mini-stroke) with no clear cause found after testing.
- You do not have certain heart conditions like atrial fibrillation, a recent heart attack, or a weak heart pump.
- You do not have diabetes or heart failure that already requires a similar drug.
- You have been referred for an implantable loop recorder (a small device under your skin) to check for hidden irregular heartbeats.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving empagliflozin (a diabetes medicine that may protect the heart) before or after emergency angioplasty for a first heart attack is better than a placebo. It aims to see if this medicine can improve recovery in South Asian patients.
This trial tests whether a diabetes drug called dapagliflozin (also used for heart failure) can help people recover better after a recent heart attack. It's for adults who are already on standard blood thinners and have had a heart attack in the past week.
This trial is for people who have had a specific type of stroke (acute ischemic stroke with a large blocked vessel) and are already scheduled for a procedure to remove the clot (mechanical thrombectomy). The study will test whether giving an SGLT2 inhibitor (a diabetes medicine that also helps the heart and kidneys) before the procedure improves recovery.
This trial tests if the drug empagliflozin can improve kidney function in people hospitalized with heart failure who also develop acute kidney injury. It may help protect the kidneys while treating the heart condition.
This study tests whether a diabetes drug (empagliflozin) can improve the heart's ability to relax and fill with blood in people with non-obstructive hypertrophic cardiomyopathy, a type of heart muscle thickening. You may be able to join if you have this condition and are not currently taking an SGLT2 inhibitor.
This trial tests whether empagliflozin, a diabetes medication, can help people with Brugada syndrome. It aims to see if the drug can reduce the risk of dangerous heart rhythms.
Hear when a new Embolic Stroke of Undetermined Source trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.